Accession Number : ADA259528


Title :   A Novel Immunoassay for Palytoxin. Phase 1


Descriptive Note : Final rept. 15 Aug 1989-15 Feb 1990


Corporate Author : STANDARD SCIENTIFICS INC NEEDHAM MA


Personal Author(s) : Hu, Chia-Ling


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a259528.pdf


Report Date : 15 Feb 1990


Pagination or Media Count : 14


Abstract : Phase I was highly successful in meeting its goals. The purpose of this research effort is the development of a novel, non-isotopic immunoassay for the detection of palytoxin. This assay must be sufficiently sensitive, specific and robust to meet the unique demands of field use. Two solid-phase immunoassay approaches were planned for evaluation using: (1) an immobilized antigen surface and (2) an immobilized antibody surface. During Phase I, the immobilized antigen approach was very successful. It attained RIA sensitivity (0.05 pmol) with a one hour assay time. Preliminary results also indicated that the use of unextracted serum did not interfere with the analysis. For feasibility studies on the antibody-coated surface approach, the FLIA has produced comparable sensitivity, but longer assay time at present. Studies using purified antibody are underway and are expected to improve significantly on the preliminary results obtained during the first monthly reporting period. During Phase II, we plan to improve the assay for palytoxin with specific emphasis on developing it as a field test by: developing a qualitative dipstick assay, optimizing the quantitative assay, and applying the FLIA to the palytoxin to maximize the robustness of the method. ...Palytoxin, Immunoassay, Non-Radioactive, Non-Enzymatic, SBIR, BD; RAI.


Descriptors :   *IMMUNOASSAY , *TOXIC DISEASES , TEST AND EVALUATION , TISSUES(BIOLOGY) , DETECTION , ENZYMES , FIELD TESTS , SENSITIVITY , FEASIBILITY STUDIES , RADIOACTIVITY , NERVOUS SYSTEM , ANTIBODIES , BLOOD SERUM , ANTIGENS , TOXINS AND ANTITOXINS , URINE , SOLID PHASES


Subject Categories : Medicine and Medical Research
      Pharmacology


Distribution Statement : APPROVED FOR PUBLIC RELEASE